Human Olfactory Neurosphere-derived Cells: A Novel Cellular Model For Parkinson's Disease.
Funder
National Health and Medical Research Council
Funding Amount
$365,126.00
Summary
ParkinsonÍs disease (PD) is an incurable, brain disease that affects 75,000 Australians with great societal cost. We are working on adult stem cells called (hONS) grown from peopleÍs olfactory mucosa (in the nose) as a research tool to study PD. Our project examines differences seen in hONS from people with PD and determines how certain cellular processes impact on the function of these cells. This work will enhance our understanding of the biology of PD and identify new targets for therapies.
Mitochondrial Function And The Role Of PGC-1a In Parkinson�s Disease
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Parkinson's Disease is the second most common neurodegenerative disease in Australia. Insights into the mechanisms causing Parkinson's disease may lead to therapeutic advances. This project will examine PGC-1a, a co-factor involved in the regulation of cellular energy metabolism, and examine it's role in the development of neuro-degeneration in Parkinson's disease. We aim to provide further understanding of cellular function in Parkinson's disease, and assist in therapeutic trials in neuro-degen ....Parkinson's Disease is the second most common neurodegenerative disease in Australia. Insights into the mechanisms causing Parkinson's disease may lead to therapeutic advances. This project will examine PGC-1a, a co-factor involved in the regulation of cellular energy metabolism, and examine it's role in the development of neuro-degeneration in Parkinson's disease. We aim to provide further understanding of cellular function in Parkinson's disease, and assist in therapeutic trials in neuro-degeneration.Read moreRead less
COmBining Memantine And Cholinesterase Inhibitors In Lewy Body Dementia Treatment Trial (COBALT)
Funder
National Health and Medical Research Council
Funding Amount
$1,218,120.00
Summary
Many people who have been diagnosed with dementia with Lewy bodies or Parkinson’s disease dementia will be prescribed drugs known as acetylcholinesterase inhibitors (e.g. donepezil, rivastigmine, galantamine) to help with their symptoms. This research trial, known as COBALT, is designed to find out whether there is any benefit from taking the drug memantine as well. Australian and UK researchers are collaborating on this trial which will recruit eligible participants from both countries.
Treating Parkinson's Disease Dementia With Nanoscaffolds
Funder
National Health and Medical Research Council
Funding Amount
$665,144.00
Summary
Several diseases, including Parkinson’s disease (PD), result in dementia. Currently, pharmacological therapy is the only treatment for PD dementia, which only offers symptomatic relief with diminished efficacy. Therefore, there is a need to develop new strategies that prevent or slow the onset of dementia. This study will utilize nanoscaffolds that facilitate the controlled delivery of therapeutic proteins to prevent or slow the death of neurons associated with dementia in PD patients.
Investigating The Clinical And Research Applications Of Whole-genome Sequencing In Parkinson Disease And Other Movement Disorders
Funder
National Health and Medical Research Council
Funding Amount
$266,623.00
Summary
There are many ‘movement disorders’ including Parkinson disease, dystonia, and hereditary spastic paraplegia. These disorders can be caused by mutations (errors in the genetic code) in different genes. The discovery of these genes has improved our understanding of the underlying disease mechanisms. We will use ‘whole genome sequencing’ to read a person’s entire genetic material in a single experiment, allowing us to identify a genetic diagnosis and to discover entirely new disease-causing genes.
Enhanced Deep Brain Stimulation Electrodes For Improved Efficacy In Parkinson’s Disease Therapy
Funder
National Health and Medical Research Council
Funding Amount
$809,940.00
Summary
We are developing an advanced Deep Brain Stimulation system to improve the treatment for Parkinson’s disease. Current devices benefit only half of the patients, due to imprecision in directing the electrical current to the ideal brain targets. Our system aims to deliver the current more selectively. Our implant will contain more and smaller electrodes. We will also use a state-of-the-art stimulator, implantable on the head, with capabilities far beyond the current technology.
Neuroprotection Against Parkinson’s Disease With Remote Photobiomodulation
Funder
National Health and Medical Research Council
Funding Amount
$314,818.00
Summary
Treating the head of rodents with low-intensity 670nm light protects against Parkinson’s disease (PD), but the large size of the human skull and brain precludes clinical translation of this treatment. We have discovered that the brain is also protected when light is targeted at peripheral tissues (e.g. a limb), overcoming problems of delivery. This project aims to optimise this treatment and better understand how it works, to lay the scientific basis for a clinical trial.
Mitochondrial Quality Control In Parkinson’s Disease: The Molecular Mechanisms Of PINK1 And Parkin
Funder
National Health and Medical Research Council
Funding Amount
$558,721.00
Summary
Parkinson’s disease is a degenerative disorder of the central nervous system in which the underlying cause is mostly unknown. To pave the way to a better understanding of what goes wrong, this study will investigate the function of PINK1 and Parkin, two genes that are mutated in inherited forms of the disease that play important roles in maintaining cellular health. The results of this study will be used in exploring new therapeutic targets for the treatment of Parkinson’s disease symptoms.